Cover Image
市場調查報告書

鹽野義製藥:產品平台分析

Shionogi & Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251722
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
鹽野義製藥:產品平台分析 Shionogi & Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年09月23日 內容資訊: 英文 68 Pages
簡介

鹽野義製藥是進行循環系統系、代謝系、感染疾病、免疫系、癌症性疼痛等領域的醫藥產品、診斷法、其他相關產品的製造銷售的製藥公司。該公司的為核心醫藥品產業,由處方箋藥、成藥、診斷藥構成。

本報告提供鹽野義製藥的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

鹽野義製藥的基本資料

  • 鹽野義製藥概要
  • 主要資訊
  • 企業資料

鹽野義製藥:R&D概要

  • 主要的治療範圍

鹽野義製藥:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

鹽野義製藥:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

鹽野義製藥:藥物簡介

鹽野義製藥:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

鹽野義製藥:最近的開發平台趨勢

鹽野義製藥:暫停中的計劃

鹽野義製藥:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • doripenem
    • lusutrombopag
    • S-234462
    • S-288310
    • S-444823
    • S-488410
    • S-5751
    • S-777469
    • S-8510
    • teceleukin
    • velneperit

鹽野義製藥:企業發表

鹽野義製藥:總公司和子公司的所在地

鹽野義製藥:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07590CDB

Summary

Global Markets Direct's, 'Shionogi & Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Shionogi & Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shionogi & Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Shionogi & Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Shionogi & Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Shionogi & Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Shionogi & Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Shionogi & Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shionogi & Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shionogi & Co., Ltd. Snapshot
    • Shionogi & Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Shionogi & Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Shionogi & Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Shionogi & Co., Ltd. - Pipeline Products Glance
    • Shionogi & Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Shionogi & Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shionogi & Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Shionogi & Co., Ltd. - Drug Profiles
    • lusutrombopag
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naldemedine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxycodone hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-414114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-555739
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-588410
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-237648
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-646240
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-649266
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-707106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STG-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-222611
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-488210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • doripenem
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydrocodone bitartrate ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-010887
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-033188
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-117957
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-120083
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Abuse Deterrent Combination Hydrocodone Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize CB2 for Pruritus
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize NPY5R for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Mycobacterium Tuberculosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shionogi & Co., Ltd. - Pipeline Analysis
    • Shionogi & Co., Ltd. - Pipeline Products by Target
    • Shionogi & Co., Ltd. - Pipeline Products by Route of Administration
    • Shionogi & Co., Ltd. - Pipeline Products by Molecule Type
    • Shionogi & Co., Ltd. - Pipeline Products by Mechanism of Action
  • Shionogi & Co., Ltd. - Recent Pipeline Updates
  • Shionogi & Co., Ltd. - Dormant Projects
  • Shionogi & Co., Ltd. - Dormant Projects
  • Shionogi & Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • doripenem
      • lusutrombopag
      • S-234462
      • S-288310
      • S-444823
      • S-488410
      • S-5751
      • S-777469
      • S-8510
      • teceleukin
      • velneperit
  • Shionogi & Co., Ltd. - Company Statement
  • Shionogi & Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Shionogi & Co., Ltd. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shionogi & Co., Ltd., Key Information
  • Shionogi & Co., Ltd., Key Facts
  • Shionogi & Co., Ltd. - Pipeline by Indication, 2015
  • Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Partnered Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Shionogi & Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Shionogi & Co., Ltd. - Pre-Registration, 2015
  • Shionogi & Co., Ltd. - Phase III, 2015
  • Shionogi & Co., Ltd. - Phase II, 2015
  • Shionogi & Co., Ltd. - Phase I, 2015
  • Shionogi & Co., Ltd. - Preclinical, 2015
  • Shionogi & Co., Ltd. - Discovery, 2015
  • Shionogi & Co., Ltd. - Pipeline by Target, 2015
  • Shionogi & Co., Ltd. - Pipeline by Route of Administration, 2015
  • Shionogi & Co., Ltd. - Pipeline by Molecule Type, 2015
  • Shionogi & Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Shionogi & Co., Ltd. - Recent Pipeline Updates, 2015
  • Shionogi & Co., Ltd. - Dormant Developmental Projects,2015
  • Shionogi & Co., Ltd. - Discontinued Pipeline Products, 2015
  • Shionogi & Co., Ltd., Other Locations
  • Shionogi & Co., Ltd., Subsidiaries
  • Shionogi & Co., Ltd., Key Manufacturing Facilities

List of Figures

  • Shionogi & Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Partnered Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • Shionogi & Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Shionogi & Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Shionogi & Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Shionogi & Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top